# US 8,465,934 B2 · Use of protein SATB2 as a marker for colorectal cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,465,934 B2
- Document ID: US8465934B2
- Status: Granted
- Kind: B2
- Application number: 13/542,723
- Filed: 2012-07-06
- Published: 2012-10-25
- Granted: 2013-06-18
- Earliest claimed: 2006-06-02
- Assignees: Atlas Antibodies AB
- Applicants: Mathias Uhlén; Fredrik Pontén
- Inventors: Mathias Uhlén; Fredrik Pontén
- Web page: https://patentgrep.com/patent/US8465934B2

## CPC

- G01N 33/57535: of the large intestine, e.g. colon, rectum or anus
- A61P 35/00: Antineoplastic agents
- G01N 2333/4703: Regulators; Modulating activity
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention provides new methods, means and uses in connection with detection, characterization and prognosis of colo-rectal cancer, via the identification of the SATB2 protein as a marker for this cancer type.

## Claims

### Claim 1

A method of treatment of a mammalian subject having a metastasis, comprising:
detecting the presence of special AT-rich sequence binding protein 2 (SATB2 protein) in a sample taken from the metastasis of the subject;
determining that the sample originated from colorectal cancer when SATB2 protein is detected in the sample; and
applying a colorectal cancer treatment to the subject.

### Claim 2 (depends on 1)

The method of claim 1, wherein said detecting step comprises applying to the sample a detectable affinity ligand capable of specific interaction with the SATB2 protein to be detected, wherein said application is performed under conditions that enable specific binding of the affinity ligand to any SATB2 protein present in the sample; removing unbound affinity ligand from the sample; and detecting any affinity ligand remaining bound to SATB2 protein in the sample.

### Claim 3 (depends on 2)

The method of claim 2, wherein the detectable affinity ligand is selected from the group consisting of antibodies, fragments of an antibody and derivatives of an antibody.

### Claim 4 (depends on 2)

The method of claim 2, wherein said detectable affinity ligand is detected using a secondary affinity ligand capable of specifically interacting with the detectable affinity ligand.

### Claim 5 (depends on 1)

The method of claim 1, wherein the detection of the SATB2 protein is conducted simultaneously or sequentially with the detection and/or quantification of cytokeratin 20 (CK20) protein in the metastasis.

### Claim 6

A method of determining whether a colorectal cancer treatment should be applied to a mammalian subject having a metastasis, comprising:
detecting the presence of special AT-rich sequence binding protein 2 (SATB2 protein) in a sample taken from the metastasis of the subject using an antibody that binds the SATB2 subsequence SEQ ID NO:1;
determining that the sample originated from colorectal cancer when SATB2 protein is detected in the sample; and
determining that the colorectal cancer treatment should be applied to the subject.